<?xml version="1.0" encoding="UTF-8"?>
<ref id="pvaa053-B43">
 <label>43</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name name-style="western">
    <surname>Haschke</surname>
    <given-names>M</given-names>
   </name>, 
   <name name-style="western">
    <surname>Schuster</surname>
    <given-names>M</given-names>
   </name>, 
   <name name-style="western">
    <surname>Poglitsch</surname>
    <given-names>M</given-names>
   </name>, 
   <name name-style="western">
    <surname>Loibner</surname>
    <given-names>H</given-names>
   </name>, 
   <name name-style="western">
    <surname>Salzberg</surname>
    <given-names>M</given-names>
   </name>, 
   <name name-style="western">
    <surname>Bruggisser</surname>
    <given-names>M</given-names>
   </name>, 
   <name name-style="western">
    <surname>Penninger</surname>
    <given-names>J</given-names>
   </name>, 
   <name name-style="western">
    <surname>Krähenbühl</surname>
    <given-names>S. Pharmacokinetics</given-names>
   </name>
  </person-group> and 
  <article-title>pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects</article-title>. 
  <source>Clin Pharmacokinet</source>
  <year>2013</year>;
  <volume>52</volume>:
  <fpage>783</fpage>–
  <lpage>792</lpage>.
  <pub-id pub-id-type="pmid">23681967</pub-id>
 </mixed-citation>
</ref>
